Jun 26th 2012 - Edison Investment Research today published a report on Allocate Software (ALL.L, LSE:ALL, LON:ALL) entitled "Robust Performance Continues". In summary, the report says:
Allocate has confirmed that full year results are expected to be in line. While the large win with the Australian Defence Force was a major factor in the H2 uplift, helped by a broadened product offering, demand within healthcare appears to have remained robust. For 2013 we see plenty of scope for earnings growth through cross-selling, a new platform rollout and licence extensions in the NHS. We see the shares as at least 20% undervalued.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »